Increased Serum Soluble OX40 in Patients with Systemic Sclerosis
Increased Serum Soluble OX40 in Patients with Systemic Sclerosis
复制标题
DOI：
10.3899/jrheum.080120
复制
发表时间：
2008-12-01
影响因子：
3.9
通讯作者：
Sato, Shinichi
中科院分区：
文献类型：
--
作者：
Komura, Kazuhiro;Yoshizaki, Ayumi;Sato, Shinichi
Objective.目的探讨系统性硬化症（SSC）患者血清可溶性OX 40（又称CD 134，肿瘤坏死因子受体超家族成员）水平及其与临床的关系。采用酶联免疫吸附试验（ELISA）检测了53例SSc患者、15例系统性红斑狼疮（SLE）患者和32例健康人血清sOX 40水平。与SLE患者（80.7 ± 1.7 pg/ml; p < 0.005）和对照组（88.2 ± 3.0 pg/ml; p < 0.0001）相比，SSc患者（125.7 ± 5.7 pg/ml）的OX 40水平显著升高。OX 40水平升高与病程小于2年有关（p <0. 05）。我们的研究结果表明，血清可溶性OX 40水平与SSc疾病的早发性相关。（2008年10月1日首次发布; J Rheumol 2008;35：2359-62; doi：10.3899/jrheum.080120）
Objective. To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSC).Methods. Serum Soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals.Results. OX40 levels were significantly elevated in SSc patients (125.7 +/- 5.7 pg/ml) compared to patients with SLE (80.7 +/- 1.7 pg/ml; p < 0.005) and controls (88.2 +/- 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05).Conclusion. Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease. (First Release Oct 1 2008; J Rheumatol 2008;35:2359-62; doi: 10.3899/jrheum.080120)